Acamprosate: A Review of Its Use in Alcohol Dependence

  title={Acamprosate: A Review of Its Use in Alcohol Dependence},
  author={Greg L. Plosker},
Acamprosate (Campral®, Aotal®, Regtect®) is one of a limited number of pharmacological treatment options approved as an adjunct to psychosocial interventions to facilitate the maintenance of abstinence in alcohol-dependent patients. It has been used in Europe, the USA and other countries for many years and was recently approved for this indication in Japan. In several randomized, double-blind, placebo-controlled trials (without active comparators), acamprosate in conjunction with psychosocial… 
Deterrent Action of Acamprosate: A Case Report
Clinicians should consider the possible deterrent effect of acamprosate in patients diagnosed with alcohol dependence syndrome and manage such patients accordingly because of the possibility of deterrent-like action of acampingrosate.
Studies on new pharmacological treatments for alcohol dependence - and the importance of objective markers of alcohol consumption
This thesis will guide you through three randomized controlled trials (RCT) on three pharmacotherapies for alcohol dependence; the antidepressant drug mirtazapine, the smoking cessation drug
Relapse prevention for alcohol use disorders: combined acamprosate and cue exposure therapy as aftercare
Only CET + acamprosate was capable of reducing alcohol consumption in the longer term, indicating that anti-craving medication may not impede CET from exerting an effect on alcohol consumption.
Alcohol addiction - the safety of available approved treatment options
All approved medications are valid tools for the treatment of AUD in patients without advanced liver disease, but for some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function.
Alcohol withdrawal syndrome results from both the alcohol and total groups were significant (p) and the small intestinal tissues were hung in the isolated organ wash on the 22nd day.
Pharmacological treatment of alcohol use disorder. Scientific evidence.
Follow-up is essential in order to assess patient compliance to treatment and monitoring outcomes, and scientific evidence has to support any therapeutic indication which should be tailored on patient needs and comorbidity by considering the individual bio-psycho-social profile.
Pharmacotherapeutic management of co-morbid alcohol and opioid use
In order to fully understand the neurobiological underpinnings of alcohol and opioid co-use and develop efficacious pharmacotherapies, the preclinical field must expand its current experimental paradigms of ‘single drug’ use to encompass polysubstance use.


Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence.
Acamprosate proved to be a safe and effective aid in treating alcohol-dependent patients and in maintaining the abstinence of patients during 2 years.
Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study.
It was concluded that acamprosate was a useful and safe pharmacotherapy in the long-term treatment of alcoholism and concomitant administration of disulfiram improved the effectiveness of acamposate.
Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence.
Limited data from a relatively well designed trial indicate that the drug has similar efficacy to that of naltrexone and that combination therapy with these two agents provides better efficacy than acamprosate monotherapy, although multicentre direct head-to-head investigations are required to fully establish the potential of this combination.
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence
An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence.
DSF is superior to ACP for preventing relapse in alcohol-dependent men with good family support and further comparisons between these two drugs in different treatment settings and populations are warranted.
Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study.
Acamprosate treatment over 180 days was consistently more effective than placebo to maintain abstinence and to diminish relapse severity and no differential effect was noted for anxiety, depression or craving.
Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
The results of this study support the efficacy of naltrexone in the relapse prevention of alcoholism amongst those with low levels of clinical depression and alcohol dependence severity.
Economic Evaluation of Campral® (Acamprosate) Compared to Placebo in Maintaining Abstinence in Alcohol-Dependent Patients
Net cost savings of 21,301 BEF (528 Euro) per patient over a 24-month period for acamprosate compared to no pharmaceutical treatment, explained by fewer acute hospitalisations for detoxification and less institutionalised rehabilitation.
Does Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence?
Among relapsers, acamprosate was significantly associated with less quantity (Q) and frequency (F) of drinking compared to placebo in each of the four follow-up periods and differences were most marked for the product Q × F (overall weekly consumption).
Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study.
A goal of abstinence was significantly associated with improved drinking outcomes, suggesting that alcohol-dependent patients with such a goal may do particularly well with counseling in a family medicine setting.